Genolution제놀루션

Genolution's revenue has held near ₩10B over the trailing year, but losses remain deep and the shares are down 32% over the past year.

Genolution sells molecular diagnostic reagents and instruments plus RNAi-based research products, mainly to universities, research institutes and companies abroad. On trailing twelve-month figures to H1 2026 it reported revenue of about ₩10.0B against an operating loss of about ₩7.4B, and free cash flow was negative at about ₩3.3B. The stock closed at ₩1,480 on 2026-10-20, with a market value of about ₩28.4B and a price-to-book ratio of 0.4.

What stands out

• Revenue rose 31.8% in 2025 to about ₩9.4B, but the operating loss widened to about ₩8.6B, an operating margin of -91.9%.
• Trailing cash of about ₩18.6B exceeds borrowings of about ₩4.5B, and liabilities are 37.5% of equity.
• The price-to-book ratio is 0.4 and the company pays no dividend, but there is no price-to-earnings ratio because earnings are negative.
• Foreign ownership fell from 1.9% to 1.1% over the past 60 days, and 20-day foreign net flows were negative.
• Recent filings are mostly insider shareholding reports, plus two 5%+ holding reports in September and October 2026. No recent news headlines are in the data.

What to watch

• Next periodic results, to see whether revenue growth can narrow the operating and net losses.
• Further 5%+ holding or insider shareholding filings, which may signal changes in major holders.
• Cash burn: trailing free cash flow was negative, so the remaining cash balance is worth tracking against the loss trend.